BioCentury
ARTICLE | Clinical News

RhC1INH regulatory update

September 28, 2009 7:00 AM UTC

EMEA accepted for review an MAA from Pharming for Rhucin recombinant human complement 1 esterase inhibitor (rhC1INH) to treat acute attacks of hereditary angioedema (HAE). The company resubmitted the...